1456616-44-6

Basic information

• Product Name: tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
• Synonyms: tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate;N-[(2S,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester;Omarigliptin Impurity 5
• CAS NO: 1456616-44-6
• Molecular Formula: C16H19F2NO4
• Molecular Weight: 327.3231664
• EINECS: -0
• Mol File: 1456616-44-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 433.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• PKA: 11.00±0.40(Predicted)
• CAS DataBase Reference: tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate(1456616-44-6)
• EPA Substance Registry System: tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate(1456616-44-6)

Safety Data

• Hazardous Substances Data: 1456616-44-6(Hazardous Substances Data)

Usage

Description

Tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate is a carbamate ester derivative with a complex chemical structure, featuring a 2,5-difluorophenyl group and a tetrahydro-2H-pyran-3-yl moiety. tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate is an analog of Omarigliptin, which is a pharmaceutical agent used in the treatment of type 2 diabetes.

Uses

Used in Pharmaceutical Industry:
Tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate is used as a therapeutic agent for the treatment of type 2 diabetes. As an analog of Omarigliptin, it is designed to help regulate blood sugar levels and improve the management of this chronic condition.
In the pharmaceutical industry, this compound is utilized for its potential to mimic the action of Omarigliptin, offering an alternative treatment option for patients with type 2 diabetes. The development and use of such analogs can lead to the discovery of more effective and safer medications for diabetes management.

Upstream product

• 951127-27-8 1-(2,5-difluorophenyl)-2-nitroethanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1456616-41-3 C₁₂H₁₁F₂NO₃ 
• 951127-28-9 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran 
• 35730-09-7 2,5-difluorobenzoyl chloride 

Downstream Products

• 1456616-66-2 C₁₆H₁₈F₂N₄O 
• 1456616-67-3 C₁₆H₁₈F₂N₄O 

Relevant articles and documents

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2- (methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran- 3-amine (23)

A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate.